top of page
428 Pharma's Patented LAI
428 Pharma is progressing both a microparticle and hydrogel forumlation.
Novel salt of escitalopram.
Protection until 2046.
Difficulties in generating LAI in SSRI/SNRIs:
-
Developing a SSRI/SNRI LAI for MDD has been a goal for pharma development for >20 years.
-
Various big pharmacos have tried and failed.
-
-
SSRI and SNRIs have very high solubility in water and very low solubility in organic solvents.
-
This creates an almost impossible formulation barrier to achieve one month release and load sufficient drug into the formulation.
-
-
428 Pharma identified a novel salt with the ideal solubility profile: This patented salt enabled us to create the worlds 1st one month SC1 LAI for treatment of depression.
-
bottom of page